|
1
|
The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease.
|
J Clin Endocrinol Metab
|
2004
|
2.44
|
|
2
|
Serum S-100beta protein is a potential biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis.
|
Diabet Med
|
2000
|
2.04
|
|
3
|
Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy.
|
Lancet
|
1999
|
1.70
|
|
4
|
Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment.
|
Clin Endocrinol (Oxf)
|
2001
|
1.31
|
|
5
|
Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers.
|
Eur J Endocrinol
|
2006
|
1.19
|
|
6
|
The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus.
|
Hum Mol Genet
|
1999
|
1.19
|
|
7
|
SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis.
|
Fam Cancer
|
2009
|
1.14
|
|
8
|
Evidence for a Graves' disease susceptibility locus at chromosome Xp11 in a United Kingdom population.
|
J Clin Endocrinol Metab
|
2001
|
1.10
|
|
9
|
Hospital management of diabetic ketoacidosis: are clinical guidelines implemented effectively?
|
Diabet Med
|
1997
|
1.04
|
|
10
|
Phaeochromocytomas presenting as acute crises after beta blockade therapy.
|
Clin Endocrinol (Oxf)
|
2006
|
1.04
|
|
11
|
Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease.
|
J Clin Endocrinol Metab
|
2000
|
0.99
|
|
12
|
CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism.
|
Clin Endocrinol (Oxf)
|
2003
|
0.97
|
|
13
|
Cushing's syndrome without excess cortisol.
|
BMJ
|
2006
|
0.95
|
|
14
|
Psychological implications of Graves' orbitopathy.
|
Eur J Endocrinol
|
2007
|
0.95
|
|
15
|
Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy.
|
Autoimmunity
|
1993
|
0.94
|
|
16
|
Lesson of the week: Deterioration of symptoms after start of thyroid hormone replacement.
|
BMJ
|
2001
|
0.92
|
|
17
|
A questionnaire survey on the management of Graves' orbitopathy in Europe.
|
Eur J Endocrinol
|
2006
|
0.91
|
|
18
|
Severe thyroid eye disease associated with primary hypothyroidism and thyroid-associated dermopathy.
|
Thyroid
|
1999
|
0.88
|
|
19
|
Octreotide and Graves' ophthalmopathy.
|
BMJ
|
1992
|
0.85
|
|
20
|
Further evidence for a susceptibility locus on chromosome 20q13.11 in families with dominant transmission of Graves disease.
|
Am J Hum Genet
|
1999
|
0.85
|
|
21
|
Plasma endothelin response to acute hypoglycaemia in adults with Type 1 diabetes.
|
Diabet Med
|
2007
|
0.85
|
|
22
|
The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines.
|
Pituitary
|
2015
|
0.84
|
|
23
|
Evidence for a new Graves disease susceptibility locus at chromosome 18q21.
|
Am J Hum Genet
|
2000
|
0.83
|
|
24
|
Metachronous testicular teratoma, testicular seminoma and papillary thyroid carcinoma occurring in a single individual: a report of two unrelated cases.
|
Eur J Cancer Care (Engl)
|
2009
|
0.81
|
|
25
|
Differentiation of autoimmune ophthalmopathy from Graves' hyperthyroidism by analysis of genetic markers.
|
Clin Endocrinol (Oxf)
|
1988
|
0.80
|
|
26
|
Acute challenge ERP as a prognostic of stimulant therapy outcome in attention-deficit hyperactivity disorder.
|
Biol Psychiatry
|
1995
|
0.78
|
|
27
|
Thyroid disease and male reproductive function.
|
J Endocrinol Invest
|
2003
|
0.78
|
|
28
|
Autoantibodies to eye muscle and orbital fibroblasts in the pathogenesis of thyroid-associated ophthalmopathy.
|
Exp Clin Endocrinol
|
1991
|
0.78
|
|
29
|
The impact of clinical guidelines on surgical management in patients with thyroid cancer.
|
Clin Oncol (R Coll Radiol)
|
2003
|
0.78
|
|
30
|
Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus.
|
Diabetes Metab Res Rev
|
2000
|
0.78
|
|
31
|
Do diabetes guidelines influence the content of referral letters by general practitioners to a diabetes specialist clinic?
|
Health Bull (Edinb)
|
2000
|
0.77
|
|
32
|
Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
|
Cytopathology
|
2014
|
0.77
|
|
33
|
Management of a pregnant patient with Graves' disease complicated by thionamide-induced neutropenia in the first trimester.
|
Clin Endocrinol (Oxf)
|
2001
|
0.76
|
|
34
|
Spontaneous rupture of Achilles tendon: missed presentation of Cushing's syndrome.
|
BMJ
|
1999
|
0.76
|
|
35
|
Glucocorticoids in the medical management of Graves' ophthalmopathy.
|
Minerva Endocrinol
|
2003
|
0.76
|
|
36
|
Clinical presentation of thyroid associated orbitopathy.
|
Thyroid
|
1998
|
0.76
|
|
37
|
Serum S-100beta protein as a biochemical marker for cerebral oedema complicating severe diabetic ketoacidosis.
|
Diabet Med
|
2001
|
0.75
|
|
38
|
Optimizing the management of differentiated thyroid cancer.
|
Clin Oncol (R Coll Radiol)
|
2000
|
0.75
|
|
39
|
Role of serum thyroglobulin measurement in patients with thyroid nodules.
|
Clin Endocrinol (Oxf)
|
2003
|
0.75
|
|
40
|
123I imaging in the follow-up of differentiated thyroid cancer.
|
Clin Oncol (R Coll Radiol)
|
2001
|
0.75
|
|
41
|
Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma.
|
Diabetes Metab Res Rev
|
2000
|
0.75
|
|
42
|
Lack of antigenicity of recombinant human thyrotropin after multiple injections in patients with differentiated thyroid cancer.
|
Thyroid
|
2000
|
0.75
|